This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2023 Jun 1;141(6):561-563.

doi: 10.1001/jamaophthalmol.2023.1794.

Cost-Efficacy in the Study of Comparative Treatments for Retinal Vein Occlusion 2-Should We Consider Step Therapy for Retinal Vein Occlusion?

Sean T Berkowitz¹, Avni P Finn¹

Affiliations

PMID: 37166784
DOI: 10.1001/jamaophthalmol.2023.1794

Comment

Cost-Efficacy in the Study of Comparative Treatments for Retinal Vein Occlusion 2-Should We Consider Step Therapy for Retinal Vein Occlusion?

Sean T Berkowitz et al. JAMA Ophthalmol. 2023.

. 2023 Jun 1;141(6):561-563.

doi: 10.1001/jamaophthalmol.2023.1794.

Authors

Sean T Berkowitz¹, Avni P Finn¹

Affiliation

¹ Department of Ophthalmology, Vanderbilt University Medical Center, Vanderbilt Eye Institute, Nashville, Tennessee.

PMID: 37166784
DOI: 10.1001/jamaophthalmol.2023.1794

No abstract available

PubMed Disclaimer

Comment on

Cost-Utility Comparison of Bevacizumab and Aflibercept in the Treatment of Central or Hemiretinal Vein Occlusion in the SCORE2 Trial.
Kymes SM, Oden NL, VanVeldhuisen PC, Scott IU, Ip MS, Blodi BA, King J; SCORE2 Investigator Group. Kymes SM, et al. JAMA Ophthalmol. 2023 Jun 1;141(6):554-561. doi: 10.1001/jamaophthalmol.2023.1463. JAMA Ophthalmol. 2023. PMID: 37166820 Free PMC article.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems